Entero Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2015 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Entero Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2015 to Q1 2024.
  • Entero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was $5.57M.
  • Entero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$6.16M, a 32.1% increase year-over-year.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.8M, a 7.97% decline from 2022.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$14.6M, a 75% increase from 2021.
  • Entero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.5M, a 79.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$6.16M $5.57M +$9.64M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$15.8M -$4.1M -$115K -2.88% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$15.7M -$3.43M -$7.83M -178% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$7.85M -$4.19M +$1.22M +22.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$9.07M -$4.07M +$5.56M +57.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$14.6M -$3.99M +$7.19M +64.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$21.8M $4.39M +$34.8M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$56.6M -$5.41M +$3.87M +41.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$60.5M -$9.63M -$1.94M -25.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$58.5M -$11.2M +$6.23M +35.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$64.8M -$30.4M -$25.1M -472% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$39.7M -$9.28M -$4.58M -97.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$35.1M -$7.69M -$2.42M -46.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q4 2020 -$32.7M -$17.4M -$16.1M -1258% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$16.6M -$5.31M -$1.12M -26.7% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-11-16
Q2 2020 -$15.4M -$4.7M +$347K +6.88% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$15.8M -$5.26M -$601K -12.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q4 2019 -$15.2M -$1.28M +$2.74M +68.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$17.9M -$4.19M -$1.62M -63% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$16.3M -$5.04M -$1.73M -52.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$14.6M -$4.66M -$1.03M -28.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$13.5M -$4.02M -$1.54M -62% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$12M -$2.57M +$563K +18% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$12.6M -$3.31M -$637K -23.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$11.9M -$3.63M -$824K -29.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$11.1M -$2.48M +$3.15M +55.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$14.2M -$3.13M +$63.9K +2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$14.3M -$2.67M +$1.1M +29.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$15.4M -$2.81M -$818K -41.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$14.6M -$5.63M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$3.2M -$1.32M -70.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$3.77M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$1.99M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q3 2015 -$1.87M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.